IL17A and psoriasis: Studies focused on the anti-psoriasis effects of API have demonstrated its ability to diminish the expression and secretion of pro-inflammatory cytokines, including recombinant chemokine C-C-Motif receptor 6 (CCR6), interleukin-17 (IL-17), and NF-κB, through modulation of the interleukin-23/IL-17/interleukin-22 (IL-22) axis.